Both cyclooxygenase- and cytokine-mediated inflammation are associated with carotid intima-media thickness.

[1]  B. Conrad,et al.  Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. , 2006, Stroke.

[2]  A. Larsson,et al.  Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. , 2005, Atherosclerosis.

[3]  A. Larsson,et al.  Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. , 2005, Diabetes care.

[4]  R. Sacco,et al.  Interleukin-2 levels are associated with carotid artery intima-media thickness. , 2005, Atherosclerosis.

[5]  D. Jacobs,et al.  Relation of Body Mass Index and Insulin Resistance to Cardiovascular Risk Factors, Inflammatory Factors, and Oxidative Stress During Adolescence , 2005, Circulation.

[6]  A. Larsson,et al.  Cyclooxygenase-mediated prostaglandin F2alpha is decreased in an elderly population treated with low-dose aspirin. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  J. Paramo,et al.  Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors? , 2005, European heart journal.

[8]  A. Larsson,et al.  Association of Type 2 Diabetes With Cyclooxygenase-Mediated Inflammation and Oxidative Stress in an Elderly Population , 2004, Circulation.

[9]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[10]  M. Linton,et al.  Cyclooxygenase-2 and inflammation in atherosclerosis. , 2004, Current opinion in pharmacology.

[11]  D. Tsikas,et al.  Urinary 8-iso-Prostaglandin F2&agr; as a Risk Marker in Patients With Coronary Heart Disease: A Matched Case-Control Study , 2004 .

[12]  Nader Rifai,et al.  Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. , 2004, Journal of the American College of Cardiology.

[13]  S. Verma,et al.  Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II , 2003, Circulation.

[14]  S. Verma,et al.  New Markers of Inflammation and Endothelial Cell Activation: Part I , 2003, Circulation.

[15]  L. Lind,et al.  Microdialysis-evaluated myocardial cyclooxygenase-mediated inflammation and early circulatory depression in porcine endotoxemia. , 2003, Critical care medicine.

[16]  N. Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events , 2003 .

[17]  H. Lakka,et al.  Six-Year Effect of Combined Vitamin C and E Supplementation on Atherosclerotic Progression: The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study , 2003, Circulation.

[18]  J. Cracowski,et al.  Lipid Peroxidation Is Not Increased in Patients With Untreated Mild-to-Moderate Hypertension , 2003, Hypertension.

[19]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[20]  D. Levy,et al.  Association of C-Reactive Protein With Carotid Atherosclerosis in Men and Women: The Framingham Heart Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[21]  S. Azen,et al.  Alpha-Tocopherol Supplementation in Healthy Individuals Reduces Low-Density Lipoprotein Oxidation but Not Atherosclerosis: The Vitamin E Atherosclerosis Prevention Study (VEAPS) , 2002, Circulation.

[22]  A. Hofman,et al.  Inflammatory Mediators and Cell Adhesion Molecules as Indicators of Severity of Atherosclerosis: The Rotterdam Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[23]  R. Sacco,et al.  Carotid Intima-Media Thickness Is Associated With Allelic Variants of Stromelysin-1, Interleukin-6, and Hepatic Lipase Genes: The Northern Manhattan Prospective Cohort Study , 2002, Stroke.

[24]  H. Steinmetz,et al.  C-Reactive Protein and Carotid Intimal Medial Thickness in a Community Population , 2002, Journal of cardiovascular risk.

[25]  J. Pankow,et al.  Association of C-reactive protein with markers of prevalent atherosclerotic disease. , 2001, The American journal of cardiology.

[26]  B. Halliwell,et al.  Raised levels of F2-isoprostanes and prostaglandin F2α in different rheumatic diseases , 2001 .

[27]  G. Berglund,et al.  Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.

[28]  C. Bouchard,et al.  Stromelysin-1 and Interleukin-6 Gene Promoter Polymorphisms Are Determinants of Asymptomatic Carotid Artery Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[29]  G. Lowe,et al.  Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. , 2000, Clinical chemistry.

[30]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[31]  A. Folsom,et al.  Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. , 2000, American journal of epidemiology.

[32]  J. Morrow,et al.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.

[33]  P. Nihoyannopoulos,et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.

[34]  G. Mancini,et al.  Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. , 1999, Clinical and investigative medicine. Medecine clinique et experimentale.

[35]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[36]  S. Basu.  Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin F2alpha: an index for inflammation via cyclooxygenase catalysed lipid peroxidation. , 1998, Prostaglandins, leukotrienes, and essential fatty acids.

[37]  S. Basu.  Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index for oxidative injury via free radical catalysed lipid peroxidation. , 1998, Prostaglandins, leukotrienes, and essential fatty acids.

[38]  P. McKeigue,et al.  Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[39]  A. Folsom,et al.  Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. , 1997, American journal of epidemiology.

[40]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[41]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[42]  F. D. de Beer,et al.  Human serum amyloid A (SAA) protein: a prominent acute‐phase reactant for clinical practice , 1996, European journal of clinical investigation.

[43]  J. Wikstrand,et al.  Methodological considerations of ultrasound investigation of intima‐media thickness and lumen diameter , 1994, Journal of internal medicine.

[44]  B. Vessby,et al.  Lower tocopherol serum levels in subjects with abdominal adiposity , 1993, Journal of internal medicine.

[45]  S Bergström,et al.  Prostaglandins: members of a new hormonal system. These physiologically very potent compounds of ubiquitous occurrence are formed from essential fatty acids. , 1967, Science.